Avid Bioservices to Present at NobleCon14

TUSTIN, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that its president and chief executive officer, Roger J. Lias, Ph.D., will deliver a corporate presentation at NobleCon14 – Noble Financial Capital Markets’ Fourteenth Annual Investor Conference, being held January 29-30, 2018 at the W Fort Lauderdale Beach Hotel in Fort Lauderdale, Florida.

Details of this presentation are as follows:

  • NobleCon14
    Time/Date: 11:30 a.m. ET on Monday, January 29, 2018
    Location: W Fort Lauderdale Beach Hotel
    Room: Studio 1

Avid’s presentation at NobleCon14 will be webcast live and available for replay at: http://ir.avidbio.com/events.cfm.

About Avid Bioservices, Inc.

Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture.  The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.  With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid’s services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support.  The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.  www.avidbio.com



Kelly Pisarev Lord 
Avid Bioservices, Inc.  
(800) 987-8256 

Stephanie Diaz (Investors)
Vida Strategic Partners
[email protected]

Tim Brons (Media)
Vida Strategic Partners
[email protected]